Broadcom named strategic vendor for Walmart virtualization solutions
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) has reported that Director Scott Myers acquired 21,000 shares of the company’s common stock on April 30, 2025. The shares were purchased at an average price of $1.3987 per share, resulting in a total transaction value of $29,372. Following this acquisition, Myers now holds 281,192 shares directly. This transaction was disclosed in a filing with the Securities and Exchange Commission.The insider purchase comes as ZNTL trades near its 52-week low of $1.01, down 87% from its yearly high of $13.24. While the company maintains a strong balance sheet with more cash than debt and a healthy current ratio of 7.3, analysts have set price targets ranging from $2.20 to $10.00. According to InvestingPro analysis, the stock appears undervalued at current levels, with 12 additional exclusive insights available to subscribers.
In other recent news, Zentalis Pharmaceuticals has been actively advancing its research and development efforts, particularly focusing on its investigational drug azenosertib. At the 2025 American Association for Cancer Research Annual Meeting, Zentalis presented four scientific posters showcasing advancements in cancer treatment research, particularly highlighting azenosertib’s potential in targeting specific genetic mutations in cancer cells. Stifel analysts have maintained a Buy rating on Zentalis with a price target of $9, reflecting confidence in the company’s progress and substantial cash reserves of $371 million. H.C. Wainwright also reaffirmed a Buy rating, albeit with a reduced price target of $10, citing promising results from the DENALI Phase 2 trial for platinum-resistant ovarian cancer.
The trial demonstrated an objective response rate of 34.9% among patients with Cyclin E1+ tumors, suggesting significant potential for azenosertib as a biomarker-driven therapy. Zentalis plans to initiate enrollment for dose confirmation in 30 patient cohorts, with the aim to transition into a potentially pivotal Phase 2 study. Additionally, the company is preparing to launch a confirmatory Phase 3 trial to support full approval. The strategic refocusing efforts, including a 40% workforce reduction, align with Zentalis’ commitment to advancing azenosertib’s development. These developments underscore the company’s dedication to addressing unmet medical needs in oncology and its potential impact on the market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.